IGC PharmaIGC +0.37%29 EBIT per Share is $-0.11 as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,180 Biotechnology companies, IGC Pharma ranks better than 71.1% on this metric.
IGC Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.11.
During the past 3 years, the average EBIT per Share Growth Rate was 32.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 10.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -1.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for IGC Pharma's EBIT per Share or its related term are showing as below:
IGC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -84.8 Med: 20.4 Max: 74.7
Current: 32
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of IGC Pharma was 74.70% per year. The lowest was -84.80% per year. And the median was 20.40% per year.
IGC's 3-Year EBIT Growth Rate is ranked better than 71.1% of 1180
companies
in the Biotechnology industry
Industry Median: 15.55
vs IGC: 32.00
IGC Pharma's EBIT for the
three
months ended in Mar. 2026 was $-2.46 Mil.
IGC Pharma (AMEX:IGC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
IGC Pharma EBIT per Share Related Terms
IGC Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for IGC Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC) has a EBIT per Share of $-0.11 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #341 out of 1180 companies in the Biotechnology industry, placing it in the top 28.9%.
Is IGC Pharma's EBIT per Share too high?
IGC Pharma's current EBIT per Share is $-0.11. Based on the distribution chart, IGC Pharma ranks #341 out of 1180 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's EBIT per Share compare to SER and NRSN?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #341 out of 1180 companies for EBIT per Share. This puts IGC Pharma in the upper half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current EBIT per Share is $-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 13.3% above its estimated fair value. The current EBIT per Share is $-0.11. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For IGC Pharma (IGC), the current EBIT per Share is $-0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.27 is trading 13.3% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
EBIT per Share: $-0.11
GF Value™: $0.24 vs. price of $0.27 (13.3% above fair value)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
